Determine the necessary mass, volume, or concentration for preparing a solution.
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at 2-8°C,Protected from light Ships Wet ice Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
PCSK9-IN-11 (compound 5r) is a potent and orally active PCSK9 inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC 50 of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be us
Appearance:Solid
IC50& Target:IC50: 5.7 μM (PCSK9)
In Vitro:PCSK9-IN-11 (compound 5r) (0-25 μM, 24 h) significantly decreases PCSK9 protein level and increases LDLR expression in a dose dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Bl
In Vivo:PCSK9-IN-11 (compound 5r) (0-1000mg/kg, IG, once) exhibits a good in vivo safety feature with the halflethal dose (LD 50 ) value of over 1000mg/kg. PCSK9-IN-11 (30mg/kg, IG, once a day for 8 weeks) significantly suppresses hepatic PCSK9 expression
Biological Activity:PCSK9-IN-11 (compound 5r) is a potent and orally active PCSK9 inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC 50 of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be us
| Molecular Weight | 381.79 |
|---|
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubility | DMSO : 125 mg/mL (327.41 mM; Need ultrasonic) |
|---|